journal article·2016-09

Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells

Pasupathi Sundaramoorthy, Thiruganesh Ramasamy, Siddhartha Kumar Mishra, Keun-Yeong Jeong, Chul Soon Yong, Jong Oh Kim, Hwan Mook Kim

Acta Biomaterialia· Volume 42
Publisher page

Abstract

Unlabelled Novel nanomaterials for the intracellular transport of therapeutic cargos have been actively sought to effectively breach cell-membrane barriers. In this study we developed novel self-micellizing anticancer lipid (SMAL)-based pro-apoptotic nanoparticles (NPs) that enhance the accumulation and chemotherapeutic efficacy of oxaliplatin (OL) in colorectal cancer cells (CRCs). We demonstrated that NPs with special affinity to caveolae could be designed and based on this specificity, NPs effectively differentiated between endothelial cells (tumor cells) and epithelial cells, without the need for a cell-specific targeting moiety. We demonstrated a remarkable uptake of OL-loaded SMAL NPs (SMAL-OL) in HCT116 and HT-29 cells via the caveolae-mediated endocytosis (CvME) pathway. The higher accumulation of SMAL-OL in the intracellular environment resulted in a significantly elevated anticancer effect compared to that of free OL. Cell cycle analysis proved G2/M phase arrest, along with substantial presence of cells in the sub-G1 phase. An immunoblot analysis indicated an upregulation of pro-apoptotic markers (Bax; caspase-3; caspase-9; and PARP1) and downregulation of Bcl-xl and the PI3K/AKT/mTOR complex, indicating a possible intrinsic apoptotic signaling pathway. Overall, the ability of SMAL NPs to confer preferential specificity towards the cell surface domain could offer an exciting means of targeted delivery without the need for receptor-ligand-type strategies. Statement of significance In this work, we developed a novel self-micellizing anticancer lipid (SMAL)-based pro-apoptotic nanoparticles (NPs) that enhance the accumulation and chemotherapeutic efficacy of oxaliplatin (OL) in colorectal cancer cells. We demonstrated that NPs with special affinity to caveolae could be realized and based on this specificity, NPs effectively differentiated between endothelial cells (tumor cells) and epithelial cells, without the need for a cell-specific targeting moiety. In addition, oxaliplatin-loaded SMAL were efficiently endocytosed by the cancer cells and represent a significant breakthrough as an effective drug delivery system with promising potential in cancer therapy. We believe this work holds promising potential for the development of next generation of multifunctional nanocarriers for an exciting means of targeted delivery without the need for receptor-ligand-type strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · Caveolin-1 and cellular processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (50)

Show source-provided references
1. Modulation of intracellular calcium levels by calcium lactate affects colon cancer cell motility through calcium-dependent calpain10.1371/journal.pone.0116984 ↗
2. Global patterns of cancer incidence and mortality rates and trends10.1158/1055-9965.EPI-10-0437 ↗
3. Cancer statistics
4. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum10.1016/0753-3322(89)90003-6 ↗
5. Cellular and molecular pharmacology of oxaliplatin1
6. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and-independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells10.1016/j.cbi.2009.08.019 ↗
7. Preparation of oxaliplatin–mesoporous silica nanoparticle conjugates and their application in cancer therapy10.1016/j.jconrel.2013.08.079 ↗
8. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a “smart” drug delivery system to breast cancer cell therapy10.1016/j.ijbiomac.2014.01.054 ↗
9. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy10.1088/0957-4484/23/7/075103 ↗
10. Cationic drug-based self-assembled polyelectrolyte complex micelles: Physicochemical, pharmacokinetic, and anticancer activity analysis10.1016/j.colsurfb.2016.06.004 ↗
11. Cross-linked polymeric micelles based on block ionomer complexes10.1016/j.mencom.2013.07.001 ↗
12. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs10.1016/j.actbio.2014.08.021 ↗
13. Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan10.1039/C5CC00482A ↗
14. Biologically active sphingolipids in cancer pathogenesis and treatment10.1038/nrc1411 ↗
15. Novel self-micellizing anticancer lipid nanoparticles induce cell death of colorectal cancer cells10.1016/j.colsurfb.2015.08.039 ↗
16. The therapeutic potential of modulating the ceramide/sphingomyelin pathway10.1172/JCI0216127 ↗
17. Specific effects of surface amines on polystyrene nanoparticles in their interactions with mesenchymal stem cells10.1021/bm901348z ↗
18. Intravascular delivery of particulate systems: does geometry really matter?10.1007/s11095-008-9697-x ↗
19. Caveolin-1 in oncogenic transformation, cancer, and metastasis10.1152/ajpcell.00458.2004 ↗
20. The multiple faces of caveolae10.1038/nrm2122 ↗
21. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α–β catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas10.1002/jcp.24034 ↗
22. Elevated expression of caveolin-1 in adenocarcinoma of the colon10.1309/YL54-CCU7-4V0P-FDUT ↗
23. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer10.1158/0008-5472.CAN-10-0730 ↗
24. Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth10.1039/C4TB01442A ↗
25. Lipid rafts: at a crossroad between cell biology and physics10.1038/ncb0107-7 ↗
26. Therapeutic applications of bioactive sphingolipids in hematological malignancies10.1002/ijc.25478 ↗
27. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells
28. Lipid metabolism: sphingolipids-from membrane constituents to signaling molecules that control cell-to-cell communications10.1097/MOL.0b013e328316c01a ↗
29. Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization10.1007/s11095-013-1251-9 ↗
30. The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles10.2147/IJN.S64794 ↗
31. Layer-by-layer coated lipid–polymer hybrid nanoparticles designed for use in anticancer drug delivery10.1016/j.carbpol.2013.11.009 ↗
32. Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments10.1166/jbn.2014.1821 ↗
33. Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape10.1021/la5015219 ↗
34. Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles10.1016/j.biomaterials.2013.01.101 ↗
35. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription10.1158/0008-5472.CAN-12-0448 ↗
36. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo10.1016/S0169-409X(01)00141-7 ↗
37. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells10.1016/j.ijpharm.2009.07.023 ↗
38. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems10.3390/molecules13102340 ↗
39. Potential in vitro and in vivo colon specific anticancer activity in a HCT-116 xenograft nude mice model: targeted delivery using enteric coated folate modified nanoparticles10.1039/C4RA15114C ↗
40. Nanocarriers’ entry into the cell: relevance to drug delivery10.1007/s00018-009-0053-z ↗
41. Biomimetic nanocarrier for direct cytosolic drug delivery10.1002/anie.200903112 ↗
42. Repression of cell cycle–related proteins by oxaliplatin but not cisplatin in human colon cancer cells10.1158/1535-7163.MCT-05-0212 ↗
43. Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization10.1007/s11095-014-1588-8 ↗
44. P21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation10.1038/sj.onc.1210516 ↗
45. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis10.1038/35071124 ↗
46. Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology, Cancer radiotherapie
47. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?10.1038/70237 ↗
48. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death10.1038/sj.onc.1203429 ↗
49. Improved cytotoxicity and multidrug resistance reversal of chitosan based polymeric micelles encapsulating oxaliplatin10.3109/1061186X.2010.499465 ↗
50. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer10.1016/j.ctrv.2014.03.004 ↗